Results: The model provided an excellent quality of ultrasound images and technique replication for US guided biopsy. Trainees reported a high level of satisfaction with the simulation program, particularly increased confidence in handling the transducer and biopsy gun and reduced anxiety about procedural complications. Conclusions: Our simulation model for educating nephrology trainees in ultrasound-guided renal biopsy is easy and inexpensive to construct, satisfactorily

mimics human tissue density, and promotes confidence among trainees. This model could be used more widely in registrar training, and its potential impact on adverse outcomes from renal biopsies warrants further investigation. 225 LEUKOCYTE CHEMOTACTIC FACTOR 2 (LECT2) AMYLOIDOSIS IN FIRST NATIONS PEOPLE

IN BRITISH COLUMBIA, Vemurafenib CANADA: A CASE SERIES H HUTTON1, M DEMARCO2, A MAGIL2, P TAYLOR3 1Department Palbociclib order of Nephrology, University of British Columbia, Vancouver, BC; 2Department of Pathology, St Paul’s Hospital, Vancouver, BC; 3Department of Nephrology, St Paul’s Hospital, Vancouver, BC, Canada Background: Leukocyte chemotactic factor 2 (LECT2) amyloidosis is a form of amyloidosis which was first identified in 2008. It is emerging as a relatively frequent type of amyloid in cases which were previously unable to be classified by immunohistochemistry. Previously reported case series indicate that LECT2 amyloid is typically renal limited. Its distinctive morphological features are of intense Congo Red staining, and deposition in the renal interstitium and vasculature as well

as glomeruli. Two previously published case series from the United States describe a higher frequency of this condition in the Hispanic population. PAK5 Case Report: Four cases of renal LECT2 amyloidosis have been diagnosed in First Nations people in Northern British Columbia, Canada over the past four years. Mass spectrometry techniques were used to make the diagnosis. All presented with slowly progressive renal impairment and minimal proteinuria, and had typical biopsy findings. Conclusions: Our centre’s experience in finding this disease exclusively in First Nations people in a particular geographic location adds weight to a hypothesis that there is an as yet unknown genetic factor which underlies the pathogenesis of this disease. The lack of extra renal manifestations or significant proteinuria mean that LECT2 amyloid is likely to be an underdiagnosed cause of chronic kidney disease. The prevalence of LECT2 amyloid in Australia is unknown, and knowledge of this condition may aid appropriate further testing in Australian patients with renal amyloidosis which previously eluded specific classification.